利伐沙班国内买的到吗？

Rivaroxaban is approved for the prevention of venous thrombosis in adult patients undergoing elective hip or knee replacement surgery. Rivaroxaban is a highly selective, oral drug that directly inhibits factor Xa. By inhibiting factor Rivaroxaban does not inhibit thrombin (activated factor II) and has no proven effect on platelets.

A dose-dependent inhibitory effect of Rivaroxaban on factor Xa activity has been observed in humans. The effect of rivaroxaban on prothrombin time (PT) has a dose-effect relationship. If NeopLastin is used for content measurement, it is closely related to the plasma concentration (correlation coefficient is 0.98). Different results may occur with other reagents. Reading the PT should be completed within seconds because the International Normalized Ratio (INR) is calibrated and validated only for coumarins and not for other anticoagulants. In patients undergoing major orthopedic surgery, 5/95th (percentile) PT was (NeopLastin) 13-25 seconds 2-4 hours after taking the tablet (when the effect is strongest) (baseline value before surgery was 12-15 seconds).

Activated partial thromboplastin time (aPTT) and HepTest prolongation are also dose-dependent; however, their use in assessing the efficacy of Rivaroxaban is not recommended. Rivaroxaban also has an effect on anti-factor Xa activity; however, there are currently no standards for calibration.

Is Rivaroxaban available in China?

In 2009, Rivaroxaban was approved for marketing by the State Food and Drug Administration. Rivaroxaban is available for purchase in China, but Rivaroxaban is a prescription drug and patients need to rely on a doctor's prescription to purchase the drug.